Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Continuing coverage of Astex Pharmaceuticals ASTX presentations at #AACR 2013:
CDK4/CDK6 inhibition is potently active in a definable subset of human neuroblastomas Rader et al (Abstract 2744)
Focused on LEE011, partnered with Novartis - click here for more on this CDK4/6 inhibitor.
Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with advanced solid tumors - Banerji et al (Abstract LB-66)
Late-breaker, so no data available yet - stay tuned until April 5th. Partnered with AstraZeneca.
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363 - Yates et al (Abstract 3352)
Generation of an acquired resistance model to the novel AKT inhibitor CCT129254 - Akan et al (Abstract 4447)
This is a precursor of AZD5363.
The molecular kinetics of p21 and Cdk4 dictates irreversible G0/G1 phase cell cycle arrest in CRPC cells - Gulappa et al (Abstract 559)
Studies with AT7519, in clinical development for multiple myeloma.
First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts - Saleh et al (LB-197)
This is the drug that, having seen this data, partner Daiichi-Sankyo just returned to ARQL. No fulltext available yet.
Presentation from Aveo Oncology AVEO:
AV-203, a fully humanized ERBB3 inhibitory antibody, reverses ERBB3-induced resistance to targeted therapies - Tyler et al (Abstract 1228)
Presentations from BioSante Pharma BPAX:
Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab - Stam et al (Abstract 1229)
Inflammatory responses with infiltrating DC and functional cytotoxic T lymphocytes in the dermal vaccination sites of GVAX/ipilimumab treated prostate cancer patients - Santegoets et al (Abstract 496)
Two more presentations from this phase 1/2 GVAX+Yervoy trial from years ago has to have been presented at least a dozen times by now!
PD-1 blockade combined with TEGVAX (TLR agonists-enhanced GVAX) can induce regression of established palpable tumors - Malm et al (Abstract 3976)